Suven Life Sciences Ltd

Suven Life Sciences Ltd

Suven Life Sciences Ltd has submitted a certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018, for the quarter ended September 30, 2026, confirming the details of securities dematerialized/rematerialized during the period have been furnished to all listed stock exchanges.

Suven Life Sciences Ltd

Suven Life Sciences Ltd has announced the closure of its trading window for all designated persons and their immediate relatives, effective from 01 October 2026, until 48 hours after the declaration of unaudited financial results for the quarter and half year ended 30 September 2026.

Suven Life Sciences Ltd

Suven Life Sciences Ltd announced the completion of patient enrollment in its global Phase-3 clinical study of Masupirdine for the treatment of Agitation associated with Alzheimer's Dementia (AAD). The study was designed to randomize approximately 375 patients, but a total of 424 patients were randomized. The Last patient last visit (LPLV) is expected by end of December 2026, and topline results are expected by May 2027.

Suven Life Sciences Ltd

Suven Life Sciences Ltd held its 37th Annual General Meeting (AGM) on August 25, 2026, through video conferencing. The meeting was attended by 152 members, and the requisite quorum was present. The Chairman delivered his speech, and the members were informed about the audited financial statements, reports of directors, and auditor's report. The meeting concluded with e-voting on all resolutions set forth in the notice.

Suven Life Sciences Ltd

Suven Life Sciences Ltd held its 37th Annual General Meeting (AGM) on August 25, 2026, through video conferencing. The meeting was attended by 152 members, and the requisite quorum was present. The Chairman delivered his speech, and the members were informed that the Auditors' Report and Secretarial Audit report did not contain any adverse remarks. The meeting transacted several items of business, including the adoption of the audited financial statements for the year ended March 31, 2026.

Suven Life Sciences Ltd

Suven Life Sciences Ltd received a Monitoring Agency Report from Crisil Ratings Limited for the quarter ended June 30, 2026, regarding the utilization of proceeds of the Preferential Issue of the company.

Suven Life Sciences Ltd

Suven Life Sciences Ltd has published its un-audited financial results for the quarter ended June 30, 2026, showing a net loss of Rs. 1611.91 lakhs for the period.

Suven Life Sciences Ltd

Suven Life Sciences Ltd has announced its un-audited financial results for the quarter ended June 30, 2026, showing a net loss of Rs. 12,76,003 lakhs for the consolidated entity and Rs. 1,61,191 lakhs for the standalone entity.

Suven Life Sciences Ltd

Suven Life Sciences Ltd has announced its un-audited financial results for the quarter ended June 30, 2026, with a net loss of Rs. 161.91 lakhs and a total comprehensive loss of Rs. 12,764.63 lakhs.

Suven Life Sciences Ltd

Suven Life Sciences Ltd has announced the notice of its 37th Annual General Meeting (AGM) and e-voting information. The AGM will be held on August 25, 2026, through video conferencing. The company has engaged KFinTech as the agency to provide e-voting facility to its members. The e-voting facility will be available from August 21, 2026, to August 24, 2026. The members are requested to note that once a vote is cast, it cannot be changed subsequently.

Suven Life Sciences Ltd

Suven Life Sciences Ltd has informed BSE that the meeting of the Board of Directors is scheduled on 06/08/2026 to consider and approve Un-Audited Financial Results for the quarter ended 30th June, 2026.

Suven Life Sciences Ltd

Suven Life Sciences Ltd has issued a letter to shareholders regarding its Annual Report for FY 2025-26, providing a web-link to access the report on the company's website. The report is available at https://www.suven.com/annualreports.aspx. Shareholders are also reminded to update their PAN, KYC details, and nomination information to ensure electronic payment of dividends.

Suven Life Sciences Ltd

Suven Life Sciences Ltd has released its Business Responsibility and Sustainability Report (BRSR) for FY 2025-26, as per Regulation 34 of SEBI (LODR) Regulations, 2015.

Suven Life Sciences Ltd

Suven Life Sciences Ltd has announced the notice of its 37th Annual General Meeting (AGM) to be held on August 25, 2026, through video conferencing. The meeting will consider the adoption of financial statements, appointment of directors, and related party transactions.

Suven Life Sciences Ltd

Suven Life Sciences Ltd has announced its Annual Report 2025-26 and Notice of 37th Annual General Meeting (AGM) scheduled to be held on August 25, 2026. The report reveals a widened revenue growth, increased R&D investment, and a net loss. The company has completed Phase 3 studies for several molecules, including Masupirdine, Samelisant, and Tenaclidine, and has initiated Phase 2 clinical trials for others.

Suven Life Sciences Ltd

Suven Life Sciences Ltd announced the allotment of 2,71,970 equity shares to eligible employees who exercised their vested options under the SLSL ESOP 2020 Scheme. The shares were issued at an exercise price of Rs. 55 each, leading to a total realization of Rs. 1,49,58,350 for the company. Consequently, the company's paid-up equity share capital increased from 26,37,20,583 shares to 26,39,92,553 shares. This allotment is a routine compliance under SEBI regulations.

Suven Life Sciences Ltd

Suven Life Sciences will participate in the BIO International Convention 2026 in San Diego to showcase its differentiated Central Nervous System (CNS) clinical candidates, including late-stage assets for Alzheimer's agitation, major depressive disorder, and narcolepsy. The company aims to engage with global pharmaceutical and biotechnology firms through 62 pre-scheduled meetings to explore partnering strategies, out-licensing, and co-development initiatives for its pipeline. This move seeks to accelerate the development and commercialization of its innovative treatments.